Drug Profile
Research programme: onchocerciasis (river blindness) therapies - Pfizer
Alternative Names: River blindness therapies - Pfizer/USCF/New York Blood CenterLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Anacor Pharmaceuticals
- Developer Anacor Pharmaceuticals; New York Blood Center; University of California at San Francisco
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Onchocerciasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Onchocerciasis in USA
- 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
- 03 Dec 2010 Early research in Onchocerciasis in USA (unspecified route)